Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019025600) SOFOSBUVIR HYDRATE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/025600 International Application No.: PCT/EP2018/071156
Publication Date: 07.02.2019 International Filing Date: 03.08.2018
IPC:
C07H 19/10 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
H
SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19
Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02
sharing nitrogen
04
Heterocyclic radicals containing only nitrogen as ring hetero atom
06
Pyrimidine radicals
10
with the saccharide radical being esterified by phosphoric or polyphosphoric acids
Applicants:
SANDOZ AG [CH/CH]; Lichtstraße 35 4056 Basel, CH
Inventors:
ALBERTINI, Manuel; AT
WERNER, Veronika; AT
SCHUSTER, Anke; AT
Agent:
HERZOG FIESSER & PARTNER PATENTANWÄLTE PARTG MBB; ALTMANN, Andreas Isartorplatz 1 80331 Muenchen, DE
Priority Data:
17184744.503.08.2017EP
Title (EN) SOFOSBUVIR HYDRATE
(FR) HYDRATE DE SOFOSBUVIR
Abstract:
(EN) The present invention relates to a hydrate of sofosbuvir, more precisely to a monohydrate of sofosbuvir, and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the sofosbuvir hydrate and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of viral hepatitis C infections.
(FR) La présente invention concerne un hydrate de sofosbuvir, plus précisément un monohydrate de sofosbuvir, et un procédé pour sa préparation. En outre, l'invention concerne une composition pharmaceutique comprenant l'hydrate de sofosbuvir et au moins un excipient pharmaceutiquement acceptable. La composition pharmaceutique selon la présente invention peut être utilisée en tant que médicament, en particulier dans le traitement d'infections virales par l'hépatite C.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)